Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19357103 | 0.88 | FAAH (0.81) | FAAHMGLL | |
| SCHEMBL5640342 | 0.86 | FAAH (0.62) | FAAHMGLL | |
| SCHEMBL425580 | 0.85 | FAAH (0.72) | FAAHMGLL | |
| SCHEMBL425438 | 0.84 | FAAH (0.60) | FAAHMGLL | |
| SCHEMBL427664 | 0.84 | FAAH (0.70) | FAAHMGLL | |
| SCHEMBL425789 | 0.84 | FAAH (0.70) | FAAHMGLL | |
| SCHEMBL426951 | 0.81 | FAAH (0.71) | FAAHMGLL | |
| SCHEMBL426681 | 0.81 | MGLL (0.71) | FAAHMGLL | |
| SCHEMBL427310 | 0.81 | MGLL (0.71) | FAAHMGLL | |
| SCHEMBL427655 | 0.80 | FAAH (0.69) | FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| EP-1554259-B1 | NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-27 | — | — | EP | disclosed |
| EP-1554259-A1 | NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004035550-A1 | NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | FAAH 144/4885MGLL 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.